HMGA2 cooperates with either p27^kip1 deficiency or Cdk4^R24C mutation in pituitary tumorigenesis

References

• Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007;7(12):899–910. doi:10.1038/nrc2271. PMID:18004397.
   PubMed Web of Science ®Google Scholar
• Fedele M, Berlingieri MT, Scala S, et al. Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene. 1998;17(4):413–418. doi: 10.1038/sj.onc.1201952. PMID:9696033.
   PubMed Web of Science ®Google Scholar
• Wood LJ, Maher JF, Bunton TE, et al. The oncogenic properties of the HMG-I gene family. Cancer Res. 2000;60(15):4256–4261. doi: Published August 2000. PMID:10945639.
   PubMed Web of Science ®Google Scholar
• Thanos D, Maniatis T. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell. 1995;83(7):1091–1100. doi:10.1016/0092-8674(95)90136-1. PMID:8548797.
   PubMed Web of Science ®Google Scholar
• Finelli P, Pierantoni GM, Giardino D, et al. The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Res. 2002;62(8):2398–2405. doi: Published April 2002. PMID:11956103.
   PubMed Web of Science ®Google Scholar
• Pierantoni GM, Finelli P, Valtorta E, et al. High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocr Relat Cancer. 2005;12(4):867–874. doi:10.1677/erc.1.01049. PMID:16322327.
   PubMed Web of Science ®Google Scholar
• Qian ZR, Asa SL, Siomi H, et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol. 2009;22(3):431–441. doi:10.1038/modpathol.2008.202. PMID:19136928.
   PubMed Web of Science ®Google Scholar
• Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene. 2002;21(20):3190–3198. doi:10.1038/sj.onc.1205428. PMID:12082634.
   PubMed Web of Science ®Google Scholar
• Fedele M, Pentimalli F, Baldassarre G, et al.: Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene. 2005;24(21):3427–3435. doi:10.1038/sj.onc.1208501. PMID:15735694.
   PubMed Web of Science ®Google Scholar
• Fedele M, Fusco A. Role of the high mobility group A proteins in the regulation of pituitary cell cycle. J Mol Endocrinol. 2010;44(6):309–318. doi:10.1677/JME-09-0178. PMID:20219853.
   PubMed Web of Science ®Google Scholar
• Fedele M, Visone R, De Martino I, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell. 2006;9(6):459–471. doi:10.1016/j.ccr.2006.04.024. PMID:16766265.
   PubMed Web of Science ®Google Scholar
• D'Angelo D, Palmieri D, Mussnich P, et al. Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab. 2012;97(7):E1128–E1138. doi:10.1210/jc.2011-3482. PMID:22564666.
   PubMed Web of Science ®Google Scholar
• De Martino, I, Visone, R, Wierinckx A, et al. HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res. 2009;69(5):1844–1850. doi:10.1158/0008-5472.CAN-08-4133. PMID:19223528.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1(3):222–231. doi:10.1038/35106065. PMID:11902577.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–1512. doi:10.1101/gad.13.12.1501. PMID:10385618.
   PubMed Web of Science ®Google Scholar
• Pines J, Hunter T. Isolation of a human cyclin cDNA: Evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell. 1989;58(5):833–846. doi:10.1016/0092-8674(89)90936-7. PMID:2570636.
   PubMed Web of Science ®Google Scholar
• Cheng M, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999;18(6):1571–1583. doi:10.1093/emboj/18.6.1571. PMID:10075928.
   PubMed Web of Science ®Google Scholar
• Bamberger CM, Fehn M, Bamberger AM, et al. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol. 1999;140(3):250–255. doi:10.1530/eje.0.1400250. PMID:10216521.
   PubMed Web of Science ®Google Scholar
• Lidhar K, Korbonits M, Jordan S, et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab. 1999;84(10):3823–3830. doi:10.1210/jcem.84.10.6066. PMID:10523037.
   PubMed Web of Science ®Google Scholar
• Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996;85(5):733–744. doi:10.1016/S0092-8674(00)81239-8. PMID:8646781.
   PubMed Web of Science ®Google Scholar
• Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996;85(5):721–732. doi:10.1016/S0092-8674(00)81238-6. PMID:8646780.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85(5):707–720. doi:10.1016/S0092-8674(00)81237-4. PMID:8646779.
   PubMed Web of Science ®Google Scholar
• Simpson DJ, Frost SJ, Bicknell JE, et al. Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis. 2001;22(8):1149–1154. doi:10.1093/carcin/22.8.1149. PMID:11470742.
   PubMed Web of Science ®Google Scholar
• Quereda V, Malumbres M. Cell cycle control of pituitary development and disease. J Mol Endocr. 2009;42(2):75–86. doi:10.1677/JME-08-0146. doi:10.1677/JME-08-0146.
   PubMed Web of Science ®Google Scholar
• Rane SG, Dubus P, Mettus RV, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet. 1999;22(1):44–52. doi:10.1038/8751. PMID:10319860.
   PubMed Web of Science ®Google Scholar
• Sotillo R, Dubus P, Martín J, et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 2001;20(23):6637–6647. doi:10.1093/emboj/20.23.6637. PMID:11726500.
   PubMed Web of Science ®Google Scholar
• Sotillo R, Renner O, Dubus P, et al. Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res. 2005;65(9):3846–3852. doi:10.1158/0008-5472.CAN-04-4195. PMID:15867383.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15(Suppl 2):ii1–56. doi:10.1093/neuonc/not151. PMID:24137015.
   PubMed Web of Science ®Google Scholar
• Colao A, Grasso LF, Pivonello R, et al. Therapy of aggressive pituitary tumors. Expert Opin Pharmacother. 2011;12(10):1561. doi:10.1517/14656566.2011.568478. PMID:21434849.
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Kovacs K, Young WF, et al. Pituitary tumors. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004. p. 10–13.
   Google Scholar
• Syro LV, Rotondo F, Ramirez A, et al. Progress in the diagnosis and classification of pituitary adenomas. Front Endocrinol (Lausanne). 2015;6:97. doi:10.3389/fendo.2015.00097. PMID:26124750.
   PubMed Web of Science ®Google Scholar
• Lopes MB, Scheithauer BW, Schiff D. Pituitary carcinoma: diagnosis and treatment. Endocrine. 2005;28:115–121. doi:10.1385/ENDO:28:1:115. PMID:16311418.
   PubMedGoogle Scholar
• Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multi- centric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013;126(1):123–135. doi:10.1007/s00401-013-1084-y. PMID:23400299.
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Osamura RY, Klöppel G, et al. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017.
   Google Scholar
• Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol. 2014;170(4):R121–R132. doi:10.1530/EJE-13-1031. PMID:24431196.
   PubMed Web of Science ®Google Scholar
• Chesnokova V, Zonis S, Kovacs K, et al. p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA. 2008;105(45):17498–17503. doi:10.1073/pnas.0804810105. PMID:18981426.
   PubMed Web of Science ®Google Scholar
• Chesnokova V, Zonis S, Rubinek T, et al. Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res. 2007;67(21):10564–10572. doi:10.1158/0008-5472.CAN-07-0974. PMID:17975001.
   PubMed Web of Science ®Google Scholar
• Cano DA, Soto-Moreno A, Leal-Cerro A. Genetically engineered mouse models of pituitary tumors. Front Oncol. 2014;4:203. doi:10.3389/fonc.2014.00203. PMID:25136513.
   PubMedGoogle Scholar
• Müssnich P, Raverot G, Jaffrain-Rea ML, et al. Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. Cell Cycle. 2015;14(16):2590–2597. doi:10.1080/15384101.2015.1064207. PMID:26125663.
   PubMed Web of Science ®Google Scholar
• Leone V, Langella C, D'Angelo D, et al. Mir-23b and miR-130b expression is downregulated in pituitary adenomas. Mol Cell Endocrinol. 2014;390(1-2):1–7. doi:10.1016/j.mce.2014.03.002. PMID:24681352.
   PubMed Web of Science ®Google Scholar
• Donangelo I, Gutman S, Horvath E, et al. Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology. 2006;147(10):4781–4791. doi:10.1210/en.2006-0544. PMID:16809444.
   PubMed Web of Science ®Google Scholar
• Park MS, Rosai J, Nguyen HT, et al. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA. 1999;96(11):6382–6387. doi:10.1073/pnas.96.11.6382. PMID:10339596.
   PubMed Web of Science ®Google Scholar
• Hubina E, Nanzer AM, Hanson MR, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol. 2006;155(2):371–379. doi:10.1530/eje.1.02213. PMID:16868153.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang X, Klibanski A. Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Mol Cell Endocrinol. 2014;386(0):16–33. doi:10.1016/j.mce.2013.09.006. PMID:24035864.
   PubMed Web of Science ®Google Scholar
• Korbonits M, Chahal HS, Kaltsas G, et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab. 2002;87(6):2635–2643. doi:10.1210/jcem.87.6.8517. PMID:12050228.
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7(5):e36411. doi:10.1371/journal.pone.0036411. PMID:22574156.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Pivonello R. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary. 2016;19(2):210–221. doi:10.1007/s11102-015-0677-y.
   PubMed Web of Science ®Google Scholar
• Bronstein MD, Fleseriu M, Neggers S, et al. Pasireotide C2305 Study Group. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr Disord. 2016;16:16. doi:10.1186/s12902-016-0096-8. PMID:27039081.
   PubMed Web of Science ®Google Scholar
• Battista S, Fidanza V, Fedele M, et al. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res. 1999;59(19):4793–4797. doi: Published October 1999. PMID:10519386.
   PubMed Web of Science ®Google Scholar